IL273538B2 - Anti-trkb monoclonal antibodies and methods of use - Google Patents

Anti-trkb monoclonal antibodies and methods of use

Info

Publication number
IL273538B2
IL273538B2 IL273538A IL27353820A IL273538B2 IL 273538 B2 IL273538 B2 IL 273538B2 IL 273538 A IL273538 A IL 273538A IL 27353820 A IL27353820 A IL 27353820A IL 273538 B2 IL273538 B2 IL 273538B2
Authority
IL
Israel
Prior art keywords
trkb
antibody
antigen
binding fragment
seq
Prior art date
Application number
IL273538A
Other languages
English (en)
Hebrew (he)
Other versions
IL273538B1 (en
IL273538A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL273538A publication Critical patent/IL273538A/en
Publication of IL273538B1 publication Critical patent/IL273538B1/en
Publication of IL273538B2 publication Critical patent/IL273538B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL273538A 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use IL273538B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30
PCT/US2018/062863 WO2019108662A1 (en) 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use

Publications (3)

Publication Number Publication Date
IL273538A IL273538A (en) 2020-05-31
IL273538B1 IL273538B1 (en) 2024-06-01
IL273538B2 true IL273538B2 (en) 2024-10-01

Family

ID=64665125

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273538A IL273538B2 (en) 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use

Country Status (18)

Country Link
US (3) US11066474B2 (https=)
EP (1) EP3717514A1 (https=)
JP (2) JP7438937B2 (https=)
KR (1) KR20200090779A (https=)
CN (2) CN111372949B (https=)
AU (3) AU2018375340B2 (https=)
BR (1) BR112020006976A2 (https=)
CA (1) CA3083452A1 (https=)
CL (3) CL2020000855A1 (https=)
CO (1) CO2020004075A2 (https=)
EA (1) EA202090966A1 (https=)
IL (1) IL273538B2 (https=)
MA (1) MA51207A (https=)
MX (3) MX2020003550A (https=)
MY (1) MY203247A (https=)
PH (1) PH12020550409A1 (https=)
SG (1) SG11202002665UA (https=)
WO (1) WO2019108662A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
IL310006A (en) * 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
US12559560B2 (en) * 2020-01-30 2026-02-24 Fred Hutchinson Cancer Center Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
TW202342494A (zh) 2022-03-30 2023-11-01 日商肽夢想股份有限公司 具有TrkB結合活性之肽複合物
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196390A1 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corp. Agonist anti-trkb monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2712298C (en) 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10080745B2 (en) 2013-11-25 2018-09-25 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP4095161A1 (en) * 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196390A1 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corp. Agonist anti-trkb monoclonal antibodies

Also Published As

Publication number Publication date
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
AU2026200583A1 (en) 2026-02-19
MX2025001445A (es) 2025-03-07
EP3717514A1 (en) 2020-10-07
JP7438937B2 (ja) 2024-02-27
CL2020000855A1 (es) 2020-07-31
JP2024016204A (ja) 2024-02-06
US20240309100A1 (en) 2024-09-19
CN121181700A (zh) 2025-12-23
KR20200090779A (ko) 2020-07-29
US20220411515A1 (en) 2022-12-29
JP2021507677A (ja) 2021-02-25
US12037401B2 (en) 2024-07-16
IL273538B1 (en) 2024-06-01
SG11202002665UA (en) 2020-04-29
AU2018375340A1 (en) 2020-05-07
EA202090966A1 (ru) 2020-08-26
MA51207A (fr) 2020-10-07
CA3083452A1 (en) 2019-06-06
AU2018375340B2 (en) 2025-10-30
IL273538A (en) 2020-05-31
NZ763618A (en) 2025-05-02
AU2026200616A1 (en) 2026-02-19
MX2025001444A (es) 2025-03-07
WO2019108662A1 (en) 2019-06-06
CN111372949B (zh) 2026-02-03
MX2020003550A (es) 2020-08-03
MY203247A (en) 2024-06-19
CO2020004075A2 (es) 2020-08-31
CN111372949A (zh) 2020-07-03
US20190161551A1 (en) 2019-05-30
PH12020550409A1 (en) 2021-04-12
US11066474B2 (en) 2021-07-20
CL2024002612A1 (es) 2025-01-24

Similar Documents

Publication Publication Date Title
IL273538B2 (en) Anti-trkb monoclonal antibodies and methods of use
JP7080819B2 (ja) Ｐｄ－ｌ１に対する結合メンバー
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
DK2766093T3 (en) USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER
RU2009147744A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
EP3348569B1 (en) Pan elr+ cxc chemokine antibodies
US10759859B2 (en) Anti-PD-1 antibodies and uses thereof
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
US9932397B2 (en) VEGFA/Ang2 Compounds
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
JP2021507677A5 (https=)
US10975152B2 (en) TrkB agonist antibodies and methods for treating an ocular degenerative disorder characterized by degeneration of retinal ganglion cells (RGCs)
KR20190031246A (ko) VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
MX2015007831A (es) Anticuerpos bmp-6.
JP2022500455A (ja) Ｉｌ−１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
US12540187B2 (en) Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies
JP7610767B2 (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
WO2022237819A1 (zh) 抗Siglec-15抗体及其用途
JP2024517741A (ja) 抗ｎｋｇ２ｄ抗体及びその使用
WO2022228380A1 (en) Anti-cxcr2 antibodies and uses thereof
NZ763618B2 (en) Anti-trkb monoclonal antibodies and methods of use
EA050327B1 (ru) Композиции и способы получения антител против pacap
CN121517578A (zh) 同时结合VEGF及Ang-2的Fc融合蛋白及其用途
HK40111253A (zh) 抗pacap抗体的组合物和方法
RU2016137483A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом